Metsera, Inc. (MTSR) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 New York City, NY, 美国. 現任CEO為 Christopher Whitten Bernard.
MTSR 擁有 IPO日期為 2025-01-31, 93 名全職員工, 在 NASDAQ Global Select, 市值為 $7.43B.
Metsera, Inc. is a clinical-stage biotechnology company developing injectable and oral hormone analog peptides designed to treat obesity, overweight, and related metabolic disorders. The company's pipeline includes MET-097i and MET-233i for obesity and overweight management, as well as MET-002, MET-224o, MET-067i, and MET-034i for treating conditions including diabetes and obesity. Founded in 2022 and based in New York, Metsera is advancing nutrient-stimulated therapeutic candidates toward clinical development.
